|
1
|
Davis GL, Dempster J, Meler JD, Orr DW,
Walberg MW, Brown B, Berger BD, O'Connor JK and Goldstein RM:
Hepatocellular carcinoma: Management of an increasingly common
problem. Proc (Bayl Univ Med Cent). 21:266–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Di Pardo BJ, Bronson NW, Diggs BS, Thomas
CR Jr, Hunter JG and Dolan JP: The global burden of esophageal
cancer: A disability-adjusted life-year approach. World J Surg.
40:395–401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang J, Yan L and Wang W: Current status
of multimodal & combination therapy for hepatocellular
carcinoma. Indian J Med Res. 136:391–403. 2012.PubMed/NCBI
|
|
4
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Felekkis K, Touvana E, Stefanou C and
Deltas C: MicroRNAs: A newly described class of encoded molecules
that play a role in health and disease. Hippokratia. 14:236–240.
2010.PubMed/NCBI
|
|
6
|
Wahid F, Shehzad A, Khan T and Kim YY:
MicroRNAs: Synthesis, mechanism, function, and recent clinical
trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mott JL: MicroRNAs involved in tumor
suppressor and oncogene pathways: Implications for hepatobiliary
neoplasia. Hepatology. 50:630–637. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fendler A, Stephan C, Yousef GM and Jung
K: MicroRNAs as regulators of signal transduction in urological
tumors. Clin Chem. 57:954–968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roy S, Benz F, Luedde T and Roderburg C:
The role of miRNAs in the regulation of inflammatory processes
during hepatofibrogenesis. Hepatobiliary Surg Nutr. 4:24–33.
2015.PubMed/NCBI
|
|
10
|
Szabo G and Bala S: MicroRNAs in liver
disease. Nat Rev Gastroenterol Hepatol. 10:542–552. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu SH and Ghoshal K: MicroRNAs in liver
health and disease. Curr Pathobiol Rep. 1:53–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pandey R, Jackson L, Ma G and Ahmed RP:
Identification of MicroRNAs inducing adult cardiomyocyte
proliferation. Circulation. 130:A163142014.
|
|
13
|
Tsai WL and Chung RT: Viral
hepatocarcinogenesis. Oncogene. 29:2309–2324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galuppo R, Ramaiah D, Ponte OM and Gedaly
R: Molecular therapies in hepatocellular carcinoma: What can we
target? Dig Dis Sci. 59:1688–1697. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vilchez V, Turcios L, Marti F and Gedaly
R: Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma
treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qu C, He, Lu X, Dong L, Zhu Y, Zhao Q,
Jiang X, Chang P, Jiang X, Wang L, et al: Salt-inducible Kinase
(SIK1) regulates HCC progression and WNT/beta-catenin activation. J
Hepatol. 64:1076–1089. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chu Y, Fan W, Guo W, Zhang Y, Wang L, Guo
L, Duan X, Wei J and Xu G: MiR-1247-5p functions as a tumor
suppressor in human hepatocellular carcinoma by targeting Wnt3.
Oncol Rep. 38:343–351. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu Z, Wang Z, Li F, Yang J and Tang L:
MiR-138 modulates prostate cancer cell invasion and migration via
Wnt/β-catenin pathway. Mol Med Rep. 17:3140–3145. 2018.PubMed/NCBI
|
|
20
|
Tanabe H, Hayashi M, Sugimoto H, Kurimoto
K, Hirabayashi S, Kanda M, Takami H, Niwa Y, Iwata N, Kobayashi D,
et al: Abstract 3429: Oncogenic function of miR-23b-3p in
hepatocellular carcinoma. Cancer Res. 77:3429. 2017.
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fritz V and Fajas L: Metabolism and
proliferation share common regulatory pathways in cancer cells.
Oncogene. 29:4369–4377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Curran S and Murray GI: Matrix
metalloproteinases in tumor invasion and metastasis. J Pathol.
189:300–308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Symonds H, Krall L, Remington L,
Saenz-Robles M, Lowe S, Jacks T and Van Dyke T: p53-Dependent
apoptosis suppresses tumor growth and progression in vivo. Cell.
78:703–711. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martinou JC and Youle R: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gui D, Guo Y, Wang F, Liu W, Chen J, Chen
Y, Huang J and Wang N: Astragaloside IV, a novel antioxidant,
prevents glucose-induced podocyte apoptosis in vitro and in vivo.
PLoS One. 7:e398242012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen JS, Wang Q, Fu XH, Huang XH, Chen XL,
Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of
PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in
hepatocellular carcinoma: Association with MMP-9. Hepatol Res.
39:177–186. 2010. View Article : Google Scholar
|
|
28
|
Tuo H, Wang Y, Wang L, Yao B, Li Q, Wang
C, Liu Z, Han S, Yin G, Tu K and Liu Q: MiR-324-3p promotes tumor
growth through targeting DACT1 and activation of Wnt/β-catenin
pathway in hepatocellular carcinoma. Oncotarget. 8:65687–65698.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao N, Mu L, Yang W, Liu L, Liang L and
Zhang H: MicroRNA-298 represses hepatocellular carcinoma
progression by inhibiting CTNND1-mediated Wnt/β-catenin signaling.
Biomed Pharmacother. 106:483–490. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Balogh J, Victor D III, Asham EH,
Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour
HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma.
3:41–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chu R, Mo G, Duan Z, Huang M, Chang J, Li
X and Liu P: MiRNAs affect the development of hepatocellular
carcinoma via dysregulation of their biogenesis and expression.
Cell Commun Signal. 12:452014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thurnherr T, Mah WC, Lei Z, Jin Y, Rozen
SG and Lee CG: Differentially expressed miRNAs in hepatocellular
carcinoma target genes in the genetic information processing and
metabolism pathways. Sci Rep. 6:200652016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park JK, Kogure T, Nuovo GJ, Jiang J, He
L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T and
Schmittgen TD: MiR-221 silencing blocks hepatocellular carcinoma
and promotes survival. Cancer Res. 71:7608–7616. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang JG, Shi Y, Hong DF, Song M, Huang D,
Wang CY and Zhao G: MiR-148b suppresses cell proliferation and
invasion in hepatocellular carcinoma by targeting WNT1/beta-catenin
pathway. Sci Rep. 5:80872015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu K, Li X, Cao Y, Ge Y, Wang J and Shi
B: MiR-132 inhibits cell proliferation, invasion and migration of
hepatocellular carcinoma by targeting PIK3R3. Int J Oncol.
47:1585–1593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tu K, Liu Z, Yao B, Han S and Yang W:
MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT
signaling in hepatocellular carcinoma. Int J Oncol. 48:965–974.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao N, Zhang Z, Jiang BH and Shi X: Role
of PI3K/AKT/mTOR signaling in the cell cycle progression of human
prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim M, Lee HC, Tsedensodnom O, Hartley R,
Lim YS, Yu E, Merle P and Wands JR: Functional interaction between
Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin
signaling pathway in hepatocellular carcinoma cells. J Hepatol.
48:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang J, Yu C, Chen M, Tian S and Sun C:
Over-expression of TRIM37 promotes cell migration and metastasis in
hepatocellular carcinoma by activating Wnt/beta-catenin signaling.
Biochem Biophys Res Commun. 464:1120–1127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Juan S, Anling Z, Zhendong S, Ma F, Pu P,
Wang T, Zhang J, Kang C and Zhang Q: MicroRNA-200a suppresses the
Wnt/β-catenin signaling pathway by interacting with β-catenin. Int
J Oncol. 40:1162–1170. 2012.PubMed/NCBI
|
